Evidence-based management of COVID-19 in cancer patients: Guideline by the infectious diseases working party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).

Giesen N, Sprute R, Rüthrich M, Khodamoradi Y, Mellinghoff SC, Beutel G, Lueck C, Koldehoff M, Hentrich M, Sandherr M, von Bergwelt-Baildon M, Wolf HH, Hirsch HH, Wörmann B, Cornely OA, Köhler P, Schalk E, von Lilienfeld-Toal M (2021) Evidence-based management of COVID-19 in cancer patients: Guideline by the infectious diseases working party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). Eur J Cancer 140, 86-104.

Abstract

Since its first detection in China in late 2019 the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the associated infectious disease COVID-19 continue to have a major impact on global healthcare and clinical practice. Cancer patients, in particular those with haematological malignancies, seem to be at an increased risk for a severe course of infection. Deliberations to avoid or defer potentially immunosuppressive therapies in these patients need to be balanced against the overarching goal of providing optimal antineoplastic treatment. This poses a unique challenge to treating physicians. This guideline provides evidence-based recommendations regarding prevention, diagnostics and treatment of SARS-CoV-2 infection and COVID-19 as well as strategies towards safe antineoplastic care during the COVID-19 pandemic. It was prepared by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO) by critically reviewing the currently available data on SARS-CoV-2 and COVID-19 in cancer patients applying evidence-based medicine criteria.

Leibniz-HKI-Autor*innen

Marie von Lilienfeld-Toal
Maria Rüthrich

Identifier

doi: 10.1016/j.ejca.2020.09.009

PMID: 33068941